Alector (ALEC) Q2 Revenue Falls 48%
Alector (NASDAQ:ALEC), a biotechnology company focused on developing therapies for neurodegenerative diseases, reported its results for the second quarter of 2025 on August 7, 2025. The most important news from this earnings release is a sharp outperformance compared to analyst expectations, with revenue and earnings per share (EPS) both beating estimates by a wide margin. GAAP revenue came in at $7.9 million, above the expected $2.8 million (GAAP), while the net loss per share narrowed to $(0.30) (GAAP) compared to the forecasted $(0.46) GAAP EPS. The quarter also saw substantial cost controls, mainly in research and development, supporting an overall steady period despite a significant drop in revenue compared to the prior year. Management confirmed a robust cash position to support upcoming clinical milestones.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Alector pursues therapies for neurodegeneration, mainly frontotemporal dementia (FTD) and Alzheimer’s disease. Its work includes late-stage drug candidates and a proprietary technology designed to help deliver treatments effectively into the brain.
Source Fool.com
